Search review questions

Stroke and Death < 30 days · people with recently symptomatic carotid artery stenosis

Perioperative death and strokes · people with recently symptomatic carotid artery stenosis

Lenght of hospital stay · people with recently symptomatic carotid artery stenosis

Myocardial infarction < 30 days · people with recently symptomatic carotid artery stenosis

Fatigue severity at the end of pharmacological treatment (assessed by different fatigue scales) · people with stroke with fatigue

Fatigue severity at the end of non‐pharmacological treatment (assessed by different fatigue scales) · people with stroke with fatigue

Fatigue severity at the end of treatment (assessed by Fatigue Severity Scale) · people with stroke not necessarily having fatigue

Changes of fatigue scores from baseline to after treatment (assessed by energy/fatigue scale from the Medical Outcomes Study) · people with stroke not necessarily having fatigue

Proportion of participants with fatigue after treatment (assessed by the self report by participants) · people with stroke not necessarily having fatigue

Long‐term death or disability ( · patients with acute ischaemic stroke

Short‐term death ( · patients with acute ischaemic stroke

Short‐term disability assessed by the Barthel Index ( · patients with acute ischaemic stroke

Severity of neurological deficits assessed by stroke scales for neurological deficits ( · patients with acute ischaemic stroke

Clinical improvement assessed by the China Stroke Scale ( · patients with acute ischaemic stroke

Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) · patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Time‐to‐event analyses for composite of recurrent stroke or TIA · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

CI: Confidence interval;HR: hazard ratio · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder · patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Primary outcome measure: recurrent stroke (non‐fatal or fatal) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Secondary outcome: all‐cause mortality at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Secondary outcome:total serious adverse events at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Secondary outcome: the incidence of atrial fibrillation · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Time‐to‐event analyses for recurrent stroke · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Time‐to‐event analyses for recurrent stroke stratified by the type of device ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Participation Nottingham Leisure Questionnaire (0 to 60) and Subjective Index of Physical and Social Outcome (0 to 40) · adult stroke survivors

Community Walk Test Community walk test (time multiplied by level of walking aid) · adult stroke survivors

Walking Ability Questionnaire Walking Ability Questionnaire (0 to 76) · adult stroke survivors

Gait speed m/s · adult stroke survivors

Six‐Minute Walk Test Six‐Minute Walk Test (metres) · adult stroke survivors

Self‐efficacy Activities Specific Balance Confidence Scale (0 to 100) and Falls Efficacy Scale (0 to 130) · adult stroke survivors

Overall USN at discharge Barrage; Letter Cancellation; Sentence Reading; Wundt‐Jastrow Paolucci 2010 study · unilateral spatial neglect after stroke

Overall USN at · unilateral spatial neglect after stroke

Disabilities Rivermead Mobility Index Score Paolucci 2010 study · unilateral spatial neglect after stroke

Disabilities Rivermead Mobility Index Score Paolucci 2010 study · unilateral spatial neglect after stroke

Daily life functions Barthel Index score Paolucci 2010 study · unilateral spatial neglect after stroke

Daily life functions Barthel Index score Paolucci 2010 study · unilateral spatial neglect after stroke

Overall USN Shape cancellation, letter cancellation, and Bells' cancellation Lucas 2013 study · unilateral spatial neglect after stroke

Disabilities Lucas 2013 study · unilateral spatial neglect after stroke

Daily life functions Lucas 2013 study · unilateral spatial neglect after stroke

Death or dependence · people with acute ischaemic or haemorrhagic stroke

Death · people with acute ischaemic or haemorrhagic stroke

Pneumonia · people with acute ischaemic or haemorrhagic stroke

Cerebral oedema · people with acute ischaemic or haemorrhagic stroke

Pulmonary oedema · people with acute ischaemic or haemorrhagic stroke

Death or dependence · people with acute ischaemic or haemorrhagic stroke

Death · people with acute ischaemic or haemorrhagic stroke

Pneumonia · people with acute ischaemic or haemorrhagic stroke

Pulmonary oedema · people with acute ischaemic or haemorrhagic stroke